CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,448.10 | 36.80 | 0.39% |
| CAC 40 | 8,699.71 | 30.42 | 0.35% |
| DAX 40 | 26,140.13 | 13.83 | 0.05% |
| Dow JONES (US) | 53,885.10 | 464.02 | -0.85% |
| FTSE 100 | 10,867.89 | 20.41 | -0.19% |
| HKSE | 25,545.50 | 15.22 | 0.06% |
| NASDAQ | 26,348.35 | 15.09 | -0.06% |
| Nikkei 225 | 65,063.01 | 620.25 | -0.94% |
| NZX 50 Index | 13,867.04 | 91.02 | -0.65% |
| S&P 500 | 7,709.96 | 13.59 | -0.18% |
| S&P/ASX 200 | 9,265.90 | 37.10 | 0.40% |
| SSE Composite Index | 3,919.69 | 19.34 | 0.50% |